Medigene AG
MDGEF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.34 | 0.10 | -0.07 |
| FCF Yield | -51.47% | 22.93% | -16.64% | -29.81% |
| EV / EBITDA | -1.61 | 2.24 | -7.22 | -2.78 |
| Quality | ||||
| ROIC | -70.75% | -17.91% | -19.50% | -45.70% |
| Gross Margin | 72.77% | 23.72% | 54.24% | 2.97% |
| Cash Conversion Ratio | 0.93 | -1.44 | 1.08 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.76% | 57.47% | -0.15% | 1.84% |
| Free Cash Flow Growth | -243.89% | 200.83% | 56.95% | -41.56% |
| Safety | ||||
| Net Debt / EBITDA | 0.37 | -1.41 | 2.82 | 1.16 |
| Interest Coverage | -29.69 | -14.38 | -30.56 | -68.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -50.37 | 29.67 | -1.72 | 69.05 |